NCT06305416View on ClinicalTrials.gov

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

PHASE3RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetic Macular EdemaDiabetic RetinopathyMacular EdemaMacular DegenerationRetinal DiseaseRetinal Degeneration
Interventions
DRUG

Ranibizumab 10mg/ml Injection

Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks

DRUG

Lucentis

Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks

Trial Locations (1)

1209

RECRUITING

Bangladesh Eye Hospital & Institute, Dhaka

Sponsors
All Listed Sponsors
collaborator

Institute for Developing Science and Health Initiatives, Bangladesh

OTHER

lead

Incepta Pharmaceuticals Ltd

INDUSTRY

NCT06305416 - A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter